This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van de Donk, N. W. C. J. Articles by Lokhorst, H. M. Search for Related Content PubMed PubMed Citation Articles by van de Donk, N. W. C. J. Articles by Lokhorst, H. M.

Protein Geranylgeranylation Is Critical for the Regulation of Survival and Proliferation of Lymphoma Tumor Cells

¹ Departments of Immunology,
² Haematology, and
³ Pathology, University Medical Center Utrecht, Utrecht, the Netherlands

Purpose: Prenylation is essential for membrane localization and participation of proteins in various signaling pathways. The following study was conducted to examine the importance of protein farnesylation and geranylgeranylation for the regulation of lymphoma cell survival and proliferation.

Experimental Design: Lymphoma cells were treated with the ß-hydroxy-ß-methylglutaryl-CoA reductase inhibitor lovastatin, which inhibits protein farnesylation and geranylgeranylation by the depletion of intracellular pools of farnesylpyrophosphate and geranylgeranylpyrophosphate. In addition, farnesyl transferase and geranylgeranyl transferase activities were specifically inhibited by FTI-277 and GGTI-298, respectively.

Results: Only inhibition of geranylgeranylation by lovastatin led to reduction of cell viability in lymphoma cell lines and purified tumor cells from lymphoma patients in a time- and dose-dependent way. Reduction in the number of viable cells was mediated by both induction of apoptosis and inhibition of proliferation. In addition, GGTI-298 was more effective in induction of apoptosis and inhibition of proliferation than FTI-277. Apoptosis induced by inhibition of protein geranylgeranylation was associated with a reduction of Mcl-1 protein levels, collapse of the mitochondrial transmembrane potential, and caspase-3 activation. Inhibition of proliferation resulted from the induction of G₁ arrest. Furthermore, lovastatin at low concentrations sensitized lymphoma cells to dexamethasone, including cells resistant to this drug.

Conclusion: These results indicate that protein geranylgeranylation is critical for the regulation of lymphoma tumor cell survival and proliferation and that pharmacological agents such as lovastatin or geranylgeranyl transferase inhibitors, alone or in combination with other drugs, may be useful in the treatment of lymphoma.

This article has been cited by other articles:

				B. von Tresckow, E. P. von Strandmann, S. Sasse, S. Tawadros, A. Engert, and H. P. Hansen Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo Haematologica, May 1, 2007; 92(5): 682 - 685. [Abstract] [Full Text] [PDF]

				J. Fortuny, S. de Sanjose, N. Becker, M. Maynadie, P. L. Cocco, A. Staines, L. Foretova, M. Vornanen, P. Brennan, A. Nieters, et al. Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPH. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 921 - 925. [Abstract] [Full Text] [PDF]

				B. Zhang, J. Groffen, and N. Heisterkamp Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a Blood, August 15, 2005; 106(4): 1355 - 1361. [Abstract] [Full Text] [PDF]

				N. W.C.J. van de Donk, H. M. Lokhorst, E. H.J. Nijhuis, M. M.J. Kamphuis, and A. C. Bloem Geranylgeranylated Proteins are Involved in the Regulation of Myeloma Cell Growth Clin. Cancer Res., January 15, 2005; 11(2): 429 - 439. [Abstract] [Full Text] [PDF]

				X. Bi, M. Baudry, J. Liu, Y. Yao, L. Fu, F. Brucher, and G. Lynch Inhibition of Geranylgeranylation Mediates the Effects of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors on Microglia J. Biol. Chem., November 12, 2004; 279(46): 48238 - 48245. [Abstract] [Full Text] [PDF]

				R. Schmidmaier, P. Baumann, M. Simsek, F. Dayyani, B. Emmerich, and G. Meinhardt The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase Blood, September 15, 2004; 104(6): 1825 - 1832. [Abstract] [Full Text] [PDF]